Targeting of SLC25A22 Boosts the Immunotherapeutic Response in KRAS-Mutant Colorectal Cancer

Investigators demonstrated that the targeting of SLC25A22 in combination with anti-PD1 therapy synergizes to inhibit myeloid-derived suppressor cells and activate CD8+ T cells to suppress KRAS-mutant colorectal cancer growth in vivo.